Share Price and Basic Stock Data
Last Updated: November 15, 2025, 2:54 pm
| PEG Ratio | -3.54 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
IOL Chemicals & Pharmaceuticals Ltd operates in the pharmaceuticals industry and has demonstrated a steady revenue trajectory over the years. The company reported revenue of ₹2,217 Cr for the fiscal year ending in March 2023, slightly declining to ₹2,133 Cr in March 2024 and further to ₹2,079 Cr in March 2025. This represents a TTM revenue of ₹2,129 Cr, indicating a consistent revenue base despite market fluctuations. Quarterly sales trends reveal a peak of ₹587 Cr in March 2023, followed by a gradual decline with ₹504 Cr reported in March 2024. The pharmaceutical sector typically exhibits stable demand, which bodes well for IOL’s core operations. However, the declining trend in sales over recent quarters raises concerns about potential competitive pressures or market saturation. The company’s operating profit margin (OPM) stood at 10% for FY 2025, reflecting operational efficiency but lower than industry averages, suggesting room for improvement in cost management or pricing strategies.
Profitability and Efficiency Metrics
IOL Chemicals reported a net profit of ₹140 Cr for FY 2023, which decreased to ₹135 Cr in FY 2024 and further declined to ₹101 Cr in FY 2025. The net profit margin was recorded at 4.86% for FY 2025, down from 6.27% in FY 2023, indicating challenges in maintaining profitability amidst rising costs or pricing pressures. The return on equity (ROE) stood at 6.13%, while the return on capital employed (ROCE) was 8.86%, both relatively low compared to industry benchmarks, highlighting inefficiencies in capital utilization. The interest coverage ratio (ICR) of 15.22x indicates strong capacity to cover interest expenses, which is a positive sign for financial health. However, the company’s operating profit margin fluctuated, with a recent high of 16% in March 2023, suggesting potential volatility in operational performance. Overall, while IOL Chemicals maintains a reasonable profitability level, the declining trend and low efficiency metrics signal the need for strategic enhancement in operations.
Balance Sheet Strength and Financial Ratios
IOL Chemicals’ balance sheet reflects a conservative financial structure with total borrowings of ₹117 Cr against reserves of ₹1,629 Cr, providing a low debt-to-equity ratio of 0.06, which is favorable compared to industry norms. This low leverage enhances financial stability and reduces risk exposure. The company’s current ratio stood at 1.89, indicating adequate liquidity to meet short-term obligations, while the quick ratio of 1.30 further supports this assertion. However, the book value per share has significantly declined from ₹274.49 in FY 2024 to ₹57.49 in FY 2025, suggesting a substantial decrease in net assets relative to shareholders’ equity. The price-to-book value (P/BV) ratio of 1.06x indicates that the market values the company slightly above its book value, reflecting investor confidence. Nonetheless, the declining trend in profitability and book value raises questions about the sustainability of this valuation in the long term.
Shareholding Pattern and Investor Confidence
The shareholding pattern of IOL Chemicals indicates a dominant promoter stake of 52.62% as of March 2025, which reflects a strong commitment from the founding members. This is a notable increase from 48.19% in March 2023, suggesting a consolidation of control. Foreign institutional investors (FIIs) hold 2.59% of shares, while domestic institutional investors (DIIs) account for only 0.02%, indicating limited institutional interest. The public shareholding stands at 44.76%, which has seen a decline from previous quarters, potentially reflecting a drop in retail investor confidence. The total number of shareholders has also decreased to 1,25,040, down from higher figures in prior periods, which may indicate waning interest. The low institutional participation and declining number of shareholders could pose risks to liquidity and stock volatility. Overall, while promoter confidence is strong, the lack of broader investor confidence could impact future capital raising and stock performance.
Outlook, Risks, and Final Insight
The outlook for IOL Chemicals hinges on its ability to stabilize revenue and enhance profitability. Key strengths include a robust balance sheet with low debt levels and a strong interest coverage ratio, which provide a safety net in uncertain times. However, the company faces significant risks from declining sales and profitability trends, which could be exacerbated by competitive pressures in the pharmaceutical sector. Additionally, the low institutional interest raises concerns about stock liquidity and investor confidence. To navigate these challenges, IOL may need to focus on operational efficiencies, explore new market opportunities, and strengthen its product portfolio. In scenarios of improved market conditions, strategic initiatives could lead to a recovery in growth and profitability. Conversely, persistent operational challenges and market pressures may hinder performance, necessitating a reevaluation of business strategies to ensure long-term sustainability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of IOL Chemicals & Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 32.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,870 Cr. | 447 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.1 Cr. | 26.0 | 29.1/17.0 | 90.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.74 Cr | 1,190.19 | 53.59 | 202.45 | 0.34% | 16.24% | 14.95% | 6.10 |
All Competitor Stocks of IOL Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 565 | 541 | 523 | 587 | 563 | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 |
| Expenses | 509 | 510 | 480 | 491 | 490 | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 |
| Operating Profit | 56 | 32 | 43 | 96 | 73 | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 |
| OPM % | 10% | 6% | 8% | 16% | 13% | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% |
| Other Income | 5 | 5 | 7 | 9 | 7 | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 |
| Interest | 3 | 4 | 5 | 5 | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 |
| Depreciation | 11 | 11 | 12 | 12 | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 |
| Profit before tax | 47 | 22 | 33 | 88 | 62 | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 |
| Tax % | 25% | 28% | 27% | 25% | 25% | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% |
| Net Profit | 35 | 16 | 24 | 65 | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 |
| EPS in Rs | 1.19 | 0.53 | 0.82 | 2.22 | 1.57 | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.70 | 1.08 | 1.16 |
Last Updated: August 20, 2025, 8:55 am
Below is a detailed analysis of the quarterly data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 552.00 Cr.. The value appears strong and on an upward trend. It has increased from 528.00 Cr. (Mar 2025) to 552.00 Cr., marking an increase of 24.00 Cr..
- For Expenses, as of Jun 2025, the value is 490.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 465.00 Cr. (Mar 2025) to 490.00 Cr., marking an increase of 25.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 12.00% (Mar 2025) to 11.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 46.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Mar 2025) to 25.00%, marking a decrease of 5.00%.
- For Net Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.16. The value appears strong and on an upward trend. It has increased from 1.08 (Mar 2025) to 1.16, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 564 | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,170 |
| Expenses | 468 | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,990 | 1,901 | 1,877 | 1,941 |
| Operating Profit | 96 | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 202 | 229 |
| OPM % | 17% | 3% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% | 11% |
| Other Income | 1 | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 23 |
| Interest | 60 | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 16 |
| Depreciation | 32 | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 77 |
| Profit before tax | 5 | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 159 |
| Tax % | 35% | -12% | 4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% | 26% | 27% | |
| Net Profit | 3 | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 116 |
| EPS in Rs | 0.23 | -2.80 | -1.42 | 0.17 | 0.99 | 8.32 | 12.70 | 15.15 | 5.64 | 4.77 | 4.61 | 3.44 | 3.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% | 22% | 23% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2333.33% | 40.30% | 112.50% | 460.00% | 746.43% | 52.32% | 23.27% | -62.70% | -15.66% | -3.57% | -25.19% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2373.63% | 72.20% | 347.50% | 286.43% | -694.11% | -29.05% | -85.97% | 47.03% | 12.09% | -21.61% |
IOL Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 2% |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | -22% |
| 3 Years: | -17% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -8% |
| 3 Years: | 10% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 7:50 am
Balance Sheet
Last Updated: August 11, 2025, 2:06 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 160 | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,332 | 1,448 | 1,553 | 1,629 |
| Borrowings | 377 | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 |
| Other Liabilities | 175 | 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 434 | 600 | 577 |
| Total Liabilities | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 |
| Fixed Assets | 411 | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | 1,170 |
| CWIP | 33 | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 | 21 |
| Other Assets | 297 | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | 1,190 | 1,168 |
| Total Assets | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 |
Below is a detailed analysis of the balance sheet data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 59.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 59.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,629.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,553.00 Cr. (Mar 2024) to 1,629.00 Cr., marking an increase of 76.00 Cr..
- For Borrowings, as of Mar 2025, the value is 117.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 33.00 Cr. (Mar 2024) to 117.00 Cr., marking an increase of 84.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 577.00 Cr.. The value appears to be improving (decreasing). It has decreased from 600.00 Cr. (Mar 2024) to 577.00 Cr., marking a decrease of 23.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,382.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,244.00 Cr. (Mar 2024) to 2,382.00 Cr., marking an increase of 138.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,170.00 Cr.. The value appears strong and on an upward trend. It has increased from 933.00 Cr. (Mar 2024) to 1,170.00 Cr., marking an increase of 237.00 Cr..
- For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 79.00 Cr..
- For Investments, as of Mar 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 21.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,168.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,190.00 Cr. (Mar 2024) to 1,168.00 Cr., marking a decrease of 22.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,382.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,244.00 Cr. (Mar 2024) to 2,382.00 Cr., marking an increase of 138.00 Cr..
Notably, the Reserves (1,629.00 Cr.) exceed the Borrowings (117.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -281.00 | -389.00 | -402.00 | -345.00 | -302.00 | 126.00 | 515.00 | 589.00 | 213.00 | 147.00 | 199.00 | 85.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 |
| Inventory Days | 190 | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 |
| Days Payable | 119 | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 |
| Cash Conversion Cycle | 103 | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 |
| Working Capital Days | -5 | 59 | 39 | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 |
| ROCE % | 11% | -3% | 4% | 12% | 15% | 56% | 68% | 54% | 18% | 14% | 12% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 25,342 | 0.2 | 1.15 | 25,342 | 2025-04-22 17:25:30 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 243 | 0.12 | 0.01 | 243 | 2025-04-22 17:25:30 | 0% |
| Groww Nifty Total Market Index Fund | 65 | 0.01 | 0 | 65 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| Diluted EPS (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| Cash EPS (Rs.) | 5.90 | 33.61 | 31.56 | 35.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 57.49 | 274.49 | 256.81 | 237.15 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 57.49 | 274.49 | 256.81 | 237.15 |
| Revenue From Operations / Share (Rs.) | 70.83 | 363.27 | 377.64 | 372.00 |
| PBDIT / Share (Rs.) | 7.65 | 44.40 | 42.80 | 49.45 |
| PBIT / Share (Rs.) | 5.20 | 33.68 | 34.94 | 42.08 |
| PBT / Share (Rs.) | 4.70 | 30.94 | 32.13 | 38.30 |
| Net Profit / Share (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| NP After MI And SOA / Share (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| PBDIT Margin (%) | 10.80 | 12.22 | 11.33 | 13.29 |
| PBIT Margin (%) | 7.34 | 9.27 | 9.25 | 11.31 |
| PBT Margin (%) | 6.63 | 8.51 | 8.50 | 10.29 |
| Net Profit Margin (%) | 4.86 | 6.30 | 6.27 | 7.67 |
| NP After MI And SOA Margin (%) | 4.86 | 6.30 | 6.27 | 7.67 |
| Return on Networth / Equity (%) | 5.98 | 8.34 | 9.22 | 12.04 |
| Return on Capital Employeed (%) | 8.61 | 11.74 | 13.09 | 17.05 |
| Return On Assets (%) | 4.24 | 5.98 | 6.88 | 8.54 |
| Total Debt / Equity (X) | 0.06 | 0.00 | 0.05 | 0.03 |
| Asset Turnover Ratio (%) | 0.89 | 0.99 | 1.11 | 0.00 |
| Current Ratio (X) | 1.89 | 2.00 | 2.02 | 2.11 |
| Quick Ratio (X) | 1.30 | 1.24 | 1.30 | 1.31 |
| Inventory Turnover Ratio (X) | 5.29 | 3.82 | 4.18 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 23.23 | 21.83 | 16.88 | 21.00 |
| Dividend Payout Ratio (CP) (%) | 13.56 | 14.87 | 12.68 | 16.69 |
| Earning Retention Ratio (%) | 76.77 | 78.17 | 83.12 | 79.00 |
| Cash Earning Retention Ratio (%) | 86.44 | 85.13 | 87.32 | 83.31 |
| Interest Coverage Ratio (X) | 15.22 | 16.19 | 15.26 | 35.02 |
| Interest Coverage Ratio (Post Tax) (X) | 7.85 | 9.35 | 9.45 | 22.91 |
| Enterprise Value (Cr.) | 1705.42 | 1979.48 | 1718.71 | 1979.92 |
| EV / Net Operating Revenue (X) | 0.82 | 0.92 | 0.77 | 0.90 |
| EV / EBITDA (X) | 7.59 | 7.59 | 6.84 | 6.82 |
| MarketCap / Net Operating Revenue (X) | 0.86 | 0.99 | 0.74 | 0.95 |
| Retention Ratios (%) | 76.76 | 78.16 | 83.11 | 78.99 |
| Price / BV (X) | 1.06 | 1.32 | 1.10 | 1.49 |
| Price / Net Operating Revenue (X) | 0.86 | 0.99 | 0.74 | 0.95 |
| EarningsYield | 0.05 | 0.06 | 0.08 | 0.08 |
After reviewing the key financial ratios for IOL Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 33.61 (Mar 24) to 5.90, marking a decrease of 27.71.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 70.83. It has decreased from 363.27 (Mar 24) to 70.83, marking a decrease of 292.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.65. This value is within the healthy range. It has decreased from 44.40 (Mar 24) to 7.65, marking a decrease of 36.75.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.20. This value is within the healthy range. It has decreased from 33.68 (Mar 24) to 5.20, marking a decrease of 28.48.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.70. This value is within the healthy range. It has decreased from 30.94 (Mar 24) to 4.70, marking a decrease of 26.24.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For PBDIT Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 12.22 (Mar 24) to 10.80, marking a decrease of 1.42.
- For PBIT Margin (%), as of Mar 25, the value is 7.34. This value is below the healthy minimum of 10. It has decreased from 9.27 (Mar 24) to 7.34, marking a decrease of 1.93.
- For PBT Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 10. It has decreased from 8.51 (Mar 24) to 6.63, marking a decrease of 1.88.
- For Net Profit Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 5. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 8. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.98. This value is below the healthy minimum of 15. It has decreased from 8.34 (Mar 24) to 5.98, marking a decrease of 2.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has decreased from 11.74 (Mar 24) to 8.61, marking a decrease of 3.13.
- For Return On Assets (%), as of Mar 25, the value is 4.24. This value is below the healthy minimum of 5. It has decreased from 5.98 (Mar 24) to 4.24, marking a decrease of 1.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.06, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has decreased from 0.99 (Mar 24) to 0.89, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.89, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.30, marking an increase of 0.06.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.29. This value is within the healthy range. It has increased from 3.82 (Mar 24) to 5.29, marking an increase of 1.47.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 21.83 (Mar 24) to 23.23, marking an increase of 1.40.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.56. This value is below the healthy minimum of 20. It has decreased from 14.87 (Mar 24) to 13.56, marking a decrease of 1.31.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.77. This value exceeds the healthy maximum of 70. It has decreased from 78.17 (Mar 24) to 76.77, marking a decrease of 1.40.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has increased from 85.13 (Mar 24) to 86.44, marking an increase of 1.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.22. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 15.22, marking a decrease of 0.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.85. This value is within the healthy range. It has decreased from 9.35 (Mar 24) to 7.85, marking a decrease of 1.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,705.42. It has decreased from 1,979.48 (Mar 24) to 1,705.42, marking a decrease of 274.06.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.82, marking a decrease of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 7.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 7.59.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
- For Retention Ratios (%), as of Mar 25, the value is 76.76. This value exceeds the healthy maximum of 70. It has decreased from 78.16 (Mar 24) to 76.76, marking a decrease of 1.40.
- For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.06, marking a decrease of 0.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in IOL Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 4.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.61% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.98% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.2 (Industry average Stock P/E: 53.59)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village & Post Office Handiaya, Barnala Punjab 148107 | investor@iolcp.com http://www.iolcp.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajender Mohan Malla | Chairman & Ind.Director |
| Mr. Varinder Gupta | Managing Director |
| Mr. Vikas Gupta | Joint Managing Director |
| Mr. Abhiraj Gupta | Executive Director |
| Mr. Kushal Kumar Rana | Director - Works |
| Mr. Harpal Singh | Independent Director |
| Mr. Sharad Tyagi | Independent Director |
| Mr. Rajni Jha | Independent Director |
FAQ
What is the intrinsic value of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 15 November 2025) is 71.45 which is 25.34% lower the current market price of 95.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,808 Cr. market cap, FY2025-2026 high/low of 127/57.5, reserves of ₹1,629 Cr, and liabilities of 2,382 Cr.
What is the Market Cap of IOL Chemicals & Pharmaceuticals Ltd?
The Market Cap of IOL Chemicals & Pharmaceuticals Ltd is 2,808 Cr..
What is the current Stock Price of IOL Chemicals & Pharmaceuticals Ltd as on 15 November 2025?
The current stock price of IOL Chemicals & Pharmaceuticals Ltd as on 15 November 2025 is 95.7.
What is the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks is 127/57.5.
What is the Stock P/E of IOL Chemicals & Pharmaceuticals Ltd?
The Stock P/E of IOL Chemicals & Pharmaceuticals Ltd is 24.2.
What is the Book Value of IOL Chemicals & Pharmaceuticals Ltd?
The Book Value of IOL Chemicals & Pharmaceuticals Ltd is 59.7.
What is the Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd is 0.84 %.
What is the ROCE of IOL Chemicals & Pharmaceuticals Ltd?
The ROCE of IOL Chemicals & Pharmaceuticals Ltd is 8.86 %.
What is the ROE of IOL Chemicals & Pharmaceuticals Ltd?
The ROE of IOL Chemicals & Pharmaceuticals Ltd is 6.13 %.
What is the Face Value of IOL Chemicals & Pharmaceuticals Ltd?
The Face Value of IOL Chemicals & Pharmaceuticals Ltd is 2.00.